Healthcare Industry News: migraine
News Release - October 8, 2012
Neuros Medical Adds Vice President of Clinical and Regulatory Affairs to Management TeamCLEVELAND--(Healthcare Sales & Marketing Network)--Neuros Medical, Inc., a medical device company, today announced the addition of Joe Schwoebel to their management team as Vice President, Clinical and Regulatory Affairs. Mr. Schwoebel is an experienced medical device executive, who will lead the Company’s programs for clinical studies, regulatory affairs and quality systems. Mr. Schwoebel has over 25 years of strategic accomplishments in clinical studies and regulatory affairs for medical technologies. He has particular focus with neuromodulation and treatment of chronic pain, both globally and domestically.
“I am very excited about the opportunity to join the team at Neuros and contribute to their ongoing success,” said Joe Schwoebel. “My prior experience with implantable stimulators and neuromodulation will permit me to rapidly move forward to support key business objectives.”
“We are pleased that Joe has joined our team and welcome his leadership in directing our long-term clinical program. This important role is consistent with our stage of development and our efforts going forward,” stated Jon J. Snyder, President and CEO of Neuros Medical. “With the recent closing of our second round of funding, led by Boston Scientific and Glengary LLC, and our pilot study currently underway, Joe will make a significant impact on our organization and will be a welcome addition to the team at Neuros.”
About Neuros Medical, Inc.
Neuros Medical, a Cleveland, Ohio based neuromodulation company, is focused on developing proprietary therapies for unmet needs to patients worldwide. The Company’s patented platform technology, Electrical Nerve Block™, is focused on the elimination of chronic pain in a variety of applications including amputation pain, chronic post-surgical pain, chronic migraine, and trigeminal neuralgia.
Source: Neuros Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.